Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 59 citing articles:

The Potential of Nanobodies for COVID-19 Diagnostics and Therapeutics
Dhaneshree Bestinee Naidoo, Anil A. Chuturgoon
Molecular Diagnosis & Therapy (2023) Vol. 27, Iss. 2, pp. 193-226
Open Access | Times Cited: 19
Protective effect of ursodeoxycholic acid on COVID-19 in patients with chronic liver disease
Yanyan Li, Na Zhu, Xinyu Cui, et al.
Frontiers in Cellular and Infection Microbiology (2023) Vol. 13
Open Access | Times Cited: 19
Efficacy and safety of molnupiravir for the treatment of SARS-CoV-2 infection: a systematic review and meta-analysis
Jakob J Malin, Stephanie Weibel, Henning Gruell, et al.
Journal of Antimicrobial Chemotherapy (2023) Vol. 78, Iss. 7, pp. 1586-1598
Open Access | Times Cited: 18
Clinical efficacy of nirmatrelvir and ritonavir combination for treating diabetic patients with COVID‐19
Jheng‐Yan Wu, Mei‐Yuan Liu, Tinghui Liu, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 6
Open Access | Times Cited: 17
Global landscape of COVID-19 research: a visualization analysis of randomized clinical trials
Sa’ed H. Zyoud
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 5
Cost-effectiveness Analysis of Nirmatrelvir/Ritonavir Compared with Molnupiravir in Patients at High Risk for Progression to Severe COVID-19 in Japan
Akira Yuasa, Hiroyuki Matsuda, Yosuke Fujii, et al.
Journal of health economics and outcomes research (2025), pp. 75-85
Open Access
Cost-effectiveness Analysis of Nirmatrelvir/Ritonavir Compared with Molnupiravir in Patients at High Risk for Progression to Severe COVID-19 in Japan
Akira Yuasa, Hiroyuki Matsuda, Yosuke Fujii, et al.
Journal of health economics and outcomes research (2025) Vol. 12, Iss. 1
Open Access
Clinical effectiveness of oral antiviral agents in older patients with COVID‐19 based on real‐world data
Ya‐Wen Tsai, Jheng‐Yan Wu, Tinghui Liu, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 6
Closed Access | Times Cited: 13
Real-World Study on Effectiveness of Molnupiravir and Nirmatrelvir–Ritonavir in Unvaccinated Patients with Chronic Respiratory Diseases with Confirmed SARS-CoV-2 Infection Managed in Out-Patient Setting
Wang Chun Kwok, Man-Fung Tsoi, Sze Him Isaac Leung, et al.
Viruses (2023) Vol. 15, Iss. 3, pp. 610-610
Open Access | Times Cited: 12
Clinical efficacy and safety of molnupiravir for nonhospitalized and hospitalized patients with COVID‐19: A systematic review and meta‐analysis of randomized control trials
Po‐Yu Huang, Tinghui Liu, Jheng‐Yan Wu, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 3
Closed Access | Times Cited: 12
Molnupiravir When Used Alone Seems to Be Safe and Effective as Outpatient COVID-19 Therapy for Hemodialyzed Patients and Kidney Transplant Recipients
Paweł Poznański, Hanna Augustyniak‐Bartosik, Anna Magiera-Żak, et al.
Viruses (2022) Vol. 14, Iss. 10, pp. 2224-2224
Open Access | Times Cited: 21
COVID-19 treatments approved in the European Union and clinical recommendations for the management of non-hospitalized and hospitalized patients
Stefania Bellino
Annals of Medicine (2022) Vol. 54, Iss. 1, pp. 2844-2848
Open Access | Times Cited: 21
Clinical effectiveness of nirmatrelvir plus ritonavir in patients with COVID‐19 and substance use disorders based on real‐world data
Tinghui Liu, Po‐Yu Huang, Jheng‐Yan Wu, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 5
Closed Access | Times Cited: 11
Effectiveness of oral antiviral agents on long‐term cardiovascular risk in nonhospitalized patients with COVID‐19: A multicenter matched cohort study
Tinghui Liu, Min‐Hsiang Chuang, Jheng‐Yan Wu, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 8
Closed Access | Times Cited: 11
Association between nirmatrelvir plus ritonavir and the outcomes of non-hospitalized obese patients with COVID-19
Jheng‐Yan Wu, Mei‐Yuan Liu, Ting-Hui Liu, et al.
International Journal of Antimicrobial Agents (2023) Vol. 62, Iss. 6, pp. 106984-106984
Closed Access | Times Cited: 11
Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: Systematic review and network meta-analysis
Meital Zur, Thalia Peselev, Stav Yanko, et al.
Antiviral Research (2023) Vol. 221, pp. 105768-105768
Closed Access | Times Cited: 11
Economic Evaluation of Wastewater Surveillance Combined with Clinical COVID-19 Screening Tests, Japan
Byung‐Kwang Yoo, Ryo Iwamoto, Ung‐il Chung, et al.
Emerging infectious diseases (2023) Vol. 29, Iss. 8
Open Access | Times Cited: 10
Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir during the Omicron era in Italy: a nationwide, cohort study
Carlo Torti, Pier Paolo Olimpieri, Paolo Bonfanti, et al.
The Lancet Regional Health - Europe (2023) Vol. 31, pp. 100684-100684
Open Access | Times Cited: 10
Cardiac Adverse Events and Remdesivir in Hospitalized Patients with Coronavirus Disease 2019 (COVID-19): A Post Hoc Safety Analysis of the Randomized DisCoVeRy Trial
Vida Terzić, Joe Miantezila Basilua, Nicolas Billard, et al.
Clinical Infectious Diseases (2024) Vol. 79, Iss. 2, pp. 382-391
Open Access | Times Cited: 3
Dryopteris crassirhizoma Nakai.: A review of its botany, traditional use, phytochemistry, pharmacological activity, toxicology and pharmacokinetics
Qian-Xiang Bai, Zhaojiong Zhang, Haipeng Tang, et al.
Journal of Ethnopharmacology (2024) Vol. 328, pp. 118109-118109
Closed Access | Times Cited: 3
Coronavirus disease 2019 rebounds following nirmatrelvir/ritonavir treatment
Chih‐Cheng Lai, Po‐Ren Hsueh
Journal of Medical Virology (2022) Vol. 95, Iss. 2
Open Access | Times Cited: 14
Phase I study, and dosing regimen selection for a pivotal COVID-19 trial of GST-HG171
H Zhang, Jing Zhou, Hong Chen, et al.
Antimicrobial Agents and Chemotherapy (2023) Vol. 68, Iss. 1
Open Access | Times Cited: 8
Effectiveness of nirmatrelvir‐ritonavir on severe outcomes of COVID‐19 in the era of vaccination and Omicron: An updated meta‐analysis
Sien Ombelet, Diego Castanares‐Zapatero, Fabian Desimpel, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 2
Open Access | Times Cited: 2
The effect of nirmatrelvir‐ritonavir on the long‐term risk of neuropsychiatric sequelae following COVID‐19
Tinghui Liu, Jheng‐Yan Wu, Po‐Yu Huang, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 7
Closed Access | Times Cited: 7
Iron Dyshomeostasis in COVID-19: Biomarkers Reveal a Functional Link to 5-Lipoxygenase Activation
Beatrice Dufrusine, Silvia Valentinuzzi, Sandra Bibbò, et al.
International Journal of Molecular Sciences (2022) Vol. 24, Iss. 1, pp. 15-15
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top